Peptifact

IGF-1 LR3 vs HGH: One Has Seven Approved Labels and Three Randomised Reviews, the Other Has No Human Study at All

Growth hormone and IGF-1 LR3 sit at opposite ends of the same hormonal chain, and their evidence files are not comparable. Somatropin has seven current US labels, placebo-controlled trials in deficient adults, two systematic reviews in healthy people and one randomised trial in athletes. IGF-1 LR3 has no registered study, no approval and no adverse-event report — and the felony statute that names growth hormone does not name it.

Robert F · Edited by Caroline S · Published 2026-11-20

Illustration: A clear glass vial with powder next to blank scientific books on a grey surface.
Illustration

Search "IGF-1 LR3 vs HGH" and the results argue about potency. The more useful comparison is of evidence, and there the two are not in the same category: growth hormone has seven current US labels, placebo-controlled trials in deficient adults, two systematic reviews in healthy people and one randomised trial in athletes. IGF-1 LR3 has no registered trial, no approval, no adverse-event report and no published human study of any design.

They are also not rival versions of one hormone. Growth hormone acts partly on tissues directly and partly by causing the liver to release IGF-1; IGF-1 LR3 is a modified copy of that second hormone. So the comparison runs along a chain, not between substitutes. Our IGF-1 LR3 side effects record covers the harms question, our Increlex vs IGF-1 LR3 page sets the analogue against the one approved IGF-1 product, and our sermorelin vs HGH page covers the upstream comparison. Nothing here is a recommendation; growth hormone treatment belongs with an endocrinologist.

Side by side

HGH (somatropin) IGF-1 LR3
What it is Growth hormone itself: 191 amino acids, recombinant human sequence Modified IGF-1: human IGF-1 with Arg at position 3 plus a 13-residue N-terminal extension, ~83 residues, ~9,111 Da
Where it sits Upstream — the pituitary hormone Downstream — an analogue of the hormone GH causes the liver to release
Binding proteins Acts through the GH receptor; IGF-1 it raises is largely bound Altered specifically to evade the IGF-binding proteins that hold IGF-1 inactive
Current US labels Seven brands (openFDA, 20 November 2026) None
Registered studies 40 for mecasermin, hundreds for somatropin 0 for "IGF-1 LR3" or "Long R3 IGF-1"
Human trials in healthy people Two systematic reviews (45 study populations) and a 96-person randomised trial None
FAERS reports Thousands across somatropin brands None naming it
Named in 21 U.S.C. 333(e) Yes — "somatrem, somatropin, or an analogue of either" No

What growth hormone has actually been shown to do

In people who lack it, the label is the record. Genotropin's current label (effective 4 August 2026) covers five paediatric indications — growth hormone deficiency, Prader-Willi syndrome, small for gestational age, Turner syndrome and idiopathic short stature — and adults with growth hormone deficiency. Its adult evidence is six randomised trials in 172 adults (85 on drug, 87 on placebo for six months): lean body mass, total body water and the lean-to-fat ratio rose while total fat mass and waist circumference fell, and bone mineral density dipped at six months before returning to baseline at twelve.

In healthy older people, two Stanford-led systematic reviews settled the question that the anti-ageing market still disputes:

Review What it pooled Body composition Performance Harms
Liu 2007 (PMID 17227934) 18 study populations, 220 GH recipients, 107 person-years, mean age 69, mean 27 weeks Fat −2.1 kg, lean +2.1 kg, weight unchanged Bone density and most lipids unchanged More soft-tissue swelling, joint pain, carpal tunnel syndrome, gynaecomastia; somewhat more new diabetes and impaired fasting glucose
Liu 2008 (PMID 18347346) 27 study samples, 303 GH recipients, mean age 27, mean 20 days Lean +2.1 kg Strength and exercise capacity did not improve; exercise lactate higher in 2 of 3 studies measuring it More soft-tissue oedema and fatigue

The 2007 review's conclusion is quoted as often as it is ignored: growth hormone "cannot be recommended as an antiaging therapy".

In athletes, the one randomised trial is unusually clean. Meinhardt 2010 (PMID 20439575) gave 96 recreationally trained athletes — 63 men and 33 women, mean age 27.9 — eight weeks of placebo, growth hormone (2 mg a day), testosterone (men only, 250 mg a week) or both, then followed them through a six-week washout. Growth hormone cut fat mass and raised lean body mass, but the lean gain came through extracellular water. Sprint capacity rose 0.71 kJ, a 3.9% relative increase, in men and women combined, and 1.7 kJ (8.3%) in men given growth hormone with testosterone. Endurance, dead-lift strength and jump height did not change significantly. The sprint gain was not maintained six weeks after the drug stopped. The trial was funded by the World Anti-Doping Agency and its authors noted the doses may be lower than those used covertly.

That is the whole measured case for growth hormone in people who do not lack it: a few kilograms of body-composition change, much of it water, one sprint measure, and a list of swelling-type adverse effects.

What IGF-1 LR3 has

Nothing, in the sense that matters here. Counted on 20 November 2026:

  • ClinicalTrials.gov: 0 studies for "IGF-1 LR3"; 0 for "Long R3 IGF-1". For contrast, 40 for mecasermin, the approved recombinant human IGF-1.
  • PubMed: 44 records for "IGF-1 LR3" and 77 for "Long R3 IGF-I" — animal, cell-culture, analytical-chemistry and doping-control work. None reports giving it to people as a study intervention.
  • openFDA adverse events: no report naming IGF-1 LR3.
  • Drugs@FDA: no application naming it.

The rationale behind the comparison is nonetheless real pharmacology. IGF-1 mediates much of growth hormone's growth-promoting effect, and the LR3 modifications exist to stop IGF-binding proteins neutralising it, which in rats extended its action. Our Increlex comparison traces that design back to the 1992 papers that built it. But a mechanism is a hypothesis about people until someone measures it, and for this molecule nobody has. The 2026 clinical review of performance peptides placed IGF-1 LR3 in its lowest evidence tier — "no peer-reviewed human studies" — and the only published laboratory analysis of a black-market vial found a form carrying a six-histidine purification tag, a protein made for biochemistry rather than for anything given to a person.

What does exist, as the nearest labelled relative, is mecasermin (Increlex): recombinant human IGF-1, approved for children with severe primary IGF-1 deficiency. Its label reports hypoglycaemia at least once in 30 of 71 children (42%), five with severe episodes and four with seizures or loss of consciousness, plus tonsillar enlargement, intracranial hypertension and a post-marketing malignancy warning. Those are the harms of unmodified IGF-1 given to children who need it, in a clinic, with glucose monitoring — not a prediction about an analogue designed to evade the binding proteins that limit IGF-1's action, which is why our side-effects page treats that label as the nearest record rather than the record.

One sentence of statute explains much of this market. 21 U.S.C. 333(e) makes it an offence, punishable by up to five years in prison — ten where a person under 18 is involved — to knowingly distribute or possess with intent to distribute human growth hormone for any human use other than one FDA has authorised and a physician has ordered. Subsection (e)(4) defines the term: "somatrem, somatropin, or an analogue of either of them." IGF-1 LR3 is an analogue of IGF-1, a different molecule, and the definition does not reach it. (Marketing any unapproved drug for human use remains unlawful under the wider Act; our peptide legality page covers that general position, and nothing here is legal advice.)

The pattern that statute predicts is what the shelves showed on 20 November 2026. Reading six research-store product feeds for both substances:

Substance Listings with a price
IGF-1 LR3, 1 mg vial Swiss Chems $53.30 (regular $104.98) · Behemoth Labz $67.46 (receptor grade and media grade alike) · Modern Aminos $64.00 · PeptidePros $89.99 (regular $125.99) — median $67.46
Somatropin (191-aa growth hormone) One listing, PureRawz "HGH GMP 98%", whose product page returned HTTP 410 "Content Removed"
Other "HGH" products The 176-191 fragment ($29.84–$78.41) and multi-peptide blends — not growth hormone

So the molecule with its own felony provision is effectively absent from these stores, while the analogue the provision does not name is openly listed with a price, down to a $13.49 0.2 mg vial. That is an observation about six catalogues on one day, not a claim about anyone's reasoning, and not a statement that either listing is lawful. It does mean a buyer comparing "IGF-1 LR3 vs HGH" in a research store is usually not comparing growth hormone with anything — the growth hormone is not there.

What a reader should take from the comparison

  • The evidence gap runs one way and is very wide. Growth hormone's effects in healthy people are measured, small and partly water; IGF-1 LR3's are unmeasured.
  • "Downstream" does not mean safer. The nearest labelled IGF-1 causes hypoglycaemia in a large minority of the children it treats, and an analogue built to escape the binding proteins is built to escape the body's main limit on that effect.
  • Absence of adverse-event reports is not absence of harm. No FAERS report names IGF-1 LR3 because nothing in that system collects reports on an unapproved research chemical.
  • The two are not interchangeable in law, in supply or in what is known about them, and any page claiming one is simply a stronger version of the other is arguing past all three.

Anyone weighing either substance for a person should be doing so with a clinician who can order a growth-hormone stimulation test and read an IGF-1 level. For what the analogue's own record holds, see our IGF-1 LR3 side effects page and IGF-1 LR3 dosage record; MuscleLedger covers the upstream drugs for training readers on its growth-hormone secretagogues page.

Reproducing the census

  • ClinicalTrials.gov API v2, query.term=IGF-1 LR3 and Long R3 IGF-1 → totalCount 0; mecasermin → 40.
  • NCBI E-utilities esearch, PubMed, terms IGF-1 LR3 (44) and Long R3 IGF-I (77).
  • openFDA /drug/label.json?search=openfda.generic_name:"somatropin"&count=openfda.brand_name.exact → seven brand labels; /drug/event.json medicinal product "IGF-1 LR3" → no matches.

Sources and dates

  • GENOTROPIN (somatropin) label, Pfizer, DailyMed set ffebf88b-d257-4542-9808-74d9b7167765, effective 4 August 2026, via openFDA — indications, dosage and clinical-studies sections read 20 November 2026.
  • openFDA label and adverse-event endpoints, and Drugs@FDA, queried 20 November 2026 for somatropin brands and for IGF-1 LR3.
  • Liu H et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007;146(2):104–15. PMID 17227934. Abstract read 20 November 2026.
  • Liu H et al. Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med 2008;148(10):747–58. PMID 18347346. Abstract read 20 November 2026.
  • Meinhardt U et al. The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial. Ann Intern Med 2010;152(9):568–77. PMID 20439575. Abstract read 20 November 2026.
  • 21 U.S.C. § 333(e), text read at govinfo.gov (USCODE-2023-title21, chapter 9, subchapter III, section 333) on 20 November 2026.
  • ClinicalTrials.gov API v2 and NCBI E-utilities counts as set out above, 20 November 2026.
  • For the analogue's structure, the black-market vial analysis and the mecasermin label figures: Francis GL et al. J Mol Endocrinol 1992;8(3):213–23 (PMID 1378742); Kohler M et al. Growth Horm IGF Res 2010;20(5):386–90 (PMID 20675162); Dominikowski A et al. Front Endocrinol 2026;17:1822475 (PMID 42395176); Increlex label, DailyMed set d5b2b0e1 — all as cited on our Increlex vs IGF-1 LR3 and IGF-1 LR3 side effects pages.
  • Public product feeds (WooCommerce store API) of Ameano Peptides, Behemoth Labz, Modern Aminos, PeptidePros, PureRawz and Swiss Chems, read 20 November 2026; the PureRawz "HGH GMP 98%" product page returned HTTP 410 and the Swiss Chems and PeptidePros IGF-1 LR3 pages were confirmed in a headless browser the same day.
  • The World Anti-Doping Agency's current Prohibited List could not be opened for this page: wada-ama.org answered an automated request with an empty response, so no anti-doping classification is stated here.

Corrections go to the contact page.

Frequently asked questions

What is the difference between IGF-1 LR3 and HGH?

They are different hormones one step apart in the same chain. HGH (somatropin) is growth hormone itself; much of what it does downstream it does by making the liver and other tissues release IGF-1. IGF-1 LR3 is a modified version of that downstream hormone, altered so that the binding proteins which normally hold IGF-1 inactive bind it far less. HGH has current approved labels and randomised trials; IGF-1 LR3 has neither.

Which is stronger, IGF-1 LR3 or HGH?

The question cannot be answered from evidence, because no study has given IGF-1 LR3 to people. Growth hormone's measured effects in healthy adults are modest and specific: about 2 kg more lean mass and 2 kg less fat in older adults, no strength gain in fit young adults, and a 3.9% sprint improvement in one trial that disappeared after stopping. There is no human figure of any kind for the analogue to set beside those.

Is IGF-1 LR3 legal and HGH not?

The statutes are not symmetrical, which is a narrow point and not legal advice. 21 U.S.C. 333(e) creates a specific felony for distributing human growth hormone for unapproved human uses, and defines that term as somatrem, somatropin or an analogue of either. IGF-1 LR3 is an analogue of IGF-1, not of somatropin, so that provision does not name it. Marketing any unapproved drug for human use remains unlawful under the wider Act, and our page on peptide legality covers the general position.

Does IGF-1 LR3 work better than HGH for muscle?

Nothing has been measured. The claim rests on reasoning — that IGF-1 mediates growth hormone's anabolic effects, so delivering IGF-1 directly should work better — and on animal work with the analogue in rats. In people, the direct IGF-1 that is approved (mecasermin, for children with severe IGF-1 deficiency) was studied for growth, not muscle, and its label records hypoglycaemia in 42% of the children in its trials.

Can IGF-1 LR3 and HGH be compared on price?

Only loosely, and the comparison says more about supply than pharmacology. On 20 November 2026 a 1 mg IGF-1 LR3 vial listed at $53.30 to $89.99 across five research stores, while somatropin itself was effectively not on sale in those same stores — one listing existed and its page had been removed. Approved somatropin is a prescription product whose price comes from pharmacies, not from these feeds.